By Josh Beckerman

Arcturus Therapeutics Holdings Inc. shares rose 26% to $23.10 after hours as the company announced a vaccine collaboration with CSL Ltd.'s CSL Seqirus.

Arcturus will receive $200 million upfront and is eligible to receive over $1.3 billion in development milestones and more than $3 billion in commercial milestones.

In addition, it is eligible to receive a 40% net profit share for Covid-19 vaccine products and up to double-digit royalties for certain other vaccines.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

November 01, 2022 19:12 ET (23:12 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
CSL (ASX:CSL)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas CSL.
CSL (ASX:CSL)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas CSL.